TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a novel anticancer agent for glioblastoma multiforme (GBM). Some GBM cell lines, however, are relatively resistant to TRAIL. Doxorubicin (DOX) can sensitize GBM cells to TRAIL-induced apoptosis, indicating that the combination of DOX...
Gespeichert in:
| Veröffentlicht in: | Journal of controlled release 2011-08, Vol.154 (1), p.93-102 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 102 |
|---|---|
| container_issue | 1 |
| container_start_page | 93 |
| container_title | Journal of controlled release |
| container_volume | 154 |
| creator | Guo, Liangran Fan, Li Pang, Zhiqing Ren, Jinfen Ren, Yulong Li, Jingwei Chen, Jie Wen, Ziyi Jiang, Xinguo |
| description | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a novel anticancer agent for glioblastoma multiforme (GBM). Some GBM cell lines, however, are relatively resistant to TRAIL. Doxorubicin (DOX) can sensitize GBM cells to TRAIL-induced apoptosis, indicating that the combination of DOX and TRAIL may be an effective strategy to kill TRAIL-resistant GBM cells. However, the therapeutic effect is limited by the short serum half-life of TRAIL, chronic cardiac toxicity of DOX, multidrug resistance (MDR) property of GBM cells and poor drug delivery across the blood-brain barrier (BBB). To solve such problems, combination treatment of TRAIL liposomes (TRAIL-LP) and DOX liposomes (DOX-LP) were developed for the first time. The
in vitro cytotoxicity study indicated that DOX-LP sensitized GBM cell line U87MG but not normal bovine caruncular epithelial cells (BCECs) to TRAIL-LP-induced apoptosis, demonstrating the safety of the combination treatment. This sensitization was accompanied by up-regulation of death receptor 5 (DR5) expression and caspase activation. Furthermore, the combination therapy of TRAIL-LP and DOX-LP displayed stronger anti-GBM effect than free drugs or liposomal drugs alone
in vivo. In summary, the combination treatment reported here showed improved therapeutic effect on GBM. Therefore, it has good potential to become a new therapeutic approach for patients with GBM.
[Display omitted] |
| doi_str_mv | 10.1016/j.jconrel.2011.05.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_888113968</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365911003014</els_id><sourcerecordid>888113968</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-1368c0ea767d28a809aea66cd7acf1101f5fcd6fb081b4221aa858349dab6a403</originalsourceid><addsrcrecordid>eNqF0UFvFCEUwHFiNHZb_QgqF-NpRpgBhjmZptHaZBMTbc_kDTxWNjPDFmaa-u2l2VWPnrj84JH_I-QNZzVnXH3c13sb54Rj3TDOayZrxvQzsuG6ayvR9_I52RSnq1bJ_oyc57xnjMlWdC_JWcMV6zvBN-T-9vvlzZbC7KiLjzGtQ7BhpjZOQ5hhCXGmOP-E2WIuaAnVbgxxGCEvcQKK3qNd6AAZHS30ADmHB6TLOsVEF0g7XMK8o9HTMRxijhPmV-SFhzHj69N5Qe6-fL69-lptv13fXF1uKyskWyreKm0ZQqc612jQrAcEpazrwHpeEnjprVN-YJoPomk4gJa6Fb2DQYFg7QX5cHz3kOL9inkxU8gWxxFmjGs2WmvO217pIuVR2hRzTujNIYUJ0i_DmXmKbfbmFNs8xTZMmhK73Ht7mrAOE7q_t_7ULeD9CUC2MPpUOob8zwnRNqppint3dB6igV0q5u5HmSQZ45rrRhTx6SiwFHsImEy2ActWXEhlA8bF8J_P_gaWW6sW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>888113968</pqid></control><display><type>article</type><title>TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Guo, Liangran ; Fan, Li ; Pang, Zhiqing ; Ren, Jinfen ; Ren, Yulong ; Li, Jingwei ; Chen, Jie ; Wen, Ziyi ; Jiang, Xinguo</creator><creatorcontrib>Guo, Liangran ; Fan, Li ; Pang, Zhiqing ; Ren, Jinfen ; Ren, Yulong ; Li, Jingwei ; Chen, Jie ; Wen, Ziyi ; Jiang, Xinguo</creatorcontrib><description>Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a novel anticancer agent for glioblastoma multiforme (GBM). Some GBM cell lines, however, are relatively resistant to TRAIL. Doxorubicin (DOX) can sensitize GBM cells to TRAIL-induced apoptosis, indicating that the combination of DOX and TRAIL may be an effective strategy to kill TRAIL-resistant GBM cells. However, the therapeutic effect is limited by the short serum half-life of TRAIL, chronic cardiac toxicity of DOX, multidrug resistance (MDR) property of GBM cells and poor drug delivery across the blood-brain barrier (BBB). To solve such problems, combination treatment of TRAIL liposomes (TRAIL-LP) and DOX liposomes (DOX-LP) were developed for the first time. The
in vitro cytotoxicity study indicated that DOX-LP sensitized GBM cell line U87MG but not normal bovine caruncular epithelial cells (BCECs) to TRAIL-LP-induced apoptosis, demonstrating the safety of the combination treatment. This sensitization was accompanied by up-regulation of death receptor 5 (DR5) expression and caspase activation. Furthermore, the combination therapy of TRAIL-LP and DOX-LP displayed stronger anti-GBM effect than free drugs or liposomal drugs alone
in vivo. In summary, the combination treatment reported here showed improved therapeutic effect on GBM. Therefore, it has good potential to become a new therapeutic approach for patients with GBM.
[Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2011.05.008</identifier><identifier>PMID: 21609741</identifier><identifier>CODEN: JCREEC</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Animals ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; apoptosis ; Apoptosis - drug effects ; Biological and medical sciences ; blood serum ; blood-brain barrier ; Blotting, Western ; caspases ; Cattle ; Cell Line, Tumor ; Cell Survival - drug effects ; Combination treatment ; cytotoxicity ; death ; Doxorubicin ; Doxorubicin - administration & dosage ; Drug Resistance, Neoplasm - drug effects ; Drug Stability ; epithelial cells ; Epithelial Cells - drug effects ; Epithelial Cells - metabolism ; Female ; General pharmacology ; Glioblastoma ; Glioblastoma - drug therapy ; Glioblastoma - metabolism ; Glioblastoma - pathology ; half life ; Humans ; Liposomes ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; multiple drug resistance ; necrosis ; patients ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; therapeutics ; TNF-Related Apoptosis-Inducing Ligand - administration & dosage ; TRAIL ; Xenograft Model Antitumor Assays</subject><ispartof>Journal of controlled release, 2011-08, Vol.154 (1), p.93-102</ispartof><rights>2011 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-1368c0ea767d28a809aea66cd7acf1101f5fcd6fb081b4221aa858349dab6a403</citedby><cites>FETCH-LOGICAL-c450t-1368c0ea767d28a809aea66cd7acf1101f5fcd6fb081b4221aa858349dab6a403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jconrel.2011.05.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24432622$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21609741$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guo, Liangran</creatorcontrib><creatorcontrib>Fan, Li</creatorcontrib><creatorcontrib>Pang, Zhiqing</creatorcontrib><creatorcontrib>Ren, Jinfen</creatorcontrib><creatorcontrib>Ren, Yulong</creatorcontrib><creatorcontrib>Li, Jingwei</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Wen, Ziyi</creatorcontrib><creatorcontrib>Jiang, Xinguo</creatorcontrib><title>TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a novel anticancer agent for glioblastoma multiforme (GBM). Some GBM cell lines, however, are relatively resistant to TRAIL. Doxorubicin (DOX) can sensitize GBM cells to TRAIL-induced apoptosis, indicating that the combination of DOX and TRAIL may be an effective strategy to kill TRAIL-resistant GBM cells. However, the therapeutic effect is limited by the short serum half-life of TRAIL, chronic cardiac toxicity of DOX, multidrug resistance (MDR) property of GBM cells and poor drug delivery across the blood-brain barrier (BBB). To solve such problems, combination treatment of TRAIL liposomes (TRAIL-LP) and DOX liposomes (DOX-LP) were developed for the first time. The
in vitro cytotoxicity study indicated that DOX-LP sensitized GBM cell line U87MG but not normal bovine caruncular epithelial cells (BCECs) to TRAIL-LP-induced apoptosis, demonstrating the safety of the combination treatment. This sensitization was accompanied by up-regulation of death receptor 5 (DR5) expression and caspase activation. Furthermore, the combination therapy of TRAIL-LP and DOX-LP displayed stronger anti-GBM effect than free drugs or liposomal drugs alone
in vivo. In summary, the combination treatment reported here showed improved therapeutic effect on GBM. Therefore, it has good potential to become a new therapeutic approach for patients with GBM.
[Display omitted]</description><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>blood serum</subject><subject>blood-brain barrier</subject><subject>Blotting, Western</subject><subject>caspases</subject><subject>Cattle</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Combination treatment</subject><subject>cytotoxicity</subject><subject>death</subject><subject>Doxorubicin</subject><subject>Doxorubicin - administration & dosage</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>Drug Stability</subject><subject>epithelial cells</subject><subject>Epithelial Cells - drug effects</subject><subject>Epithelial Cells - metabolism</subject><subject>Female</subject><subject>General pharmacology</subject><subject>Glioblastoma</subject><subject>Glioblastoma - drug therapy</subject><subject>Glioblastoma - metabolism</subject><subject>Glioblastoma - pathology</subject><subject>half life</subject><subject>Humans</subject><subject>Liposomes</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>multiple drug resistance</subject><subject>necrosis</subject><subject>patients</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>therapeutics</subject><subject>TNF-Related Apoptosis-Inducing Ligand - administration & dosage</subject><subject>TRAIL</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0UFvFCEUwHFiNHZb_QgqF-NpRpgBhjmZptHaZBMTbc_kDTxWNjPDFmaa-u2l2VWPnrj84JH_I-QNZzVnXH3c13sb54Rj3TDOayZrxvQzsuG6ayvR9_I52RSnq1bJ_oyc57xnjMlWdC_JWcMV6zvBN-T-9vvlzZbC7KiLjzGtQ7BhpjZOQ5hhCXGmOP-E2WIuaAnVbgxxGCEvcQKK3qNd6AAZHS30ADmHB6TLOsVEF0g7XMK8o9HTMRxijhPmV-SFhzHj69N5Qe6-fL69-lptv13fXF1uKyskWyreKm0ZQqc612jQrAcEpazrwHpeEnjprVN-YJoPomk4gJa6Fb2DQYFg7QX5cHz3kOL9inkxU8gWxxFmjGs2WmvO217pIuVR2hRzTujNIYUJ0i_DmXmKbfbmFNs8xTZMmhK73Ht7mrAOE7q_t_7ULeD9CUC2MPpUOob8zwnRNqppint3dB6igV0q5u5HmSQZ45rrRhTx6SiwFHsImEy2ActWXEhlA8bF8J_P_gaWW6sW</recordid><startdate>20110825</startdate><enddate>20110825</enddate><creator>Guo, Liangran</creator><creator>Fan, Li</creator><creator>Pang, Zhiqing</creator><creator>Ren, Jinfen</creator><creator>Ren, Yulong</creator><creator>Li, Jingwei</creator><creator>Chen, Jie</creator><creator>Wen, Ziyi</creator><creator>Jiang, Xinguo</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20110825</creationdate><title>TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes</title><author>Guo, Liangran ; Fan, Li ; Pang, Zhiqing ; Ren, Jinfen ; Ren, Yulong ; Li, Jingwei ; Chen, Jie ; Wen, Ziyi ; Jiang, Xinguo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-1368c0ea767d28a809aea66cd7acf1101f5fcd6fb081b4221aa858349dab6a403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>blood serum</topic><topic>blood-brain barrier</topic><topic>Blotting, Western</topic><topic>caspases</topic><topic>Cattle</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Combination treatment</topic><topic>cytotoxicity</topic><topic>death</topic><topic>Doxorubicin</topic><topic>Doxorubicin - administration & dosage</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>Drug Stability</topic><topic>epithelial cells</topic><topic>Epithelial Cells - drug effects</topic><topic>Epithelial Cells - metabolism</topic><topic>Female</topic><topic>General pharmacology</topic><topic>Glioblastoma</topic><topic>Glioblastoma - drug therapy</topic><topic>Glioblastoma - metabolism</topic><topic>Glioblastoma - pathology</topic><topic>half life</topic><topic>Humans</topic><topic>Liposomes</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>multiple drug resistance</topic><topic>necrosis</topic><topic>patients</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>therapeutics</topic><topic>TNF-Related Apoptosis-Inducing Ligand - administration & dosage</topic><topic>TRAIL</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guo, Liangran</creatorcontrib><creatorcontrib>Fan, Li</creatorcontrib><creatorcontrib>Pang, Zhiqing</creatorcontrib><creatorcontrib>Ren, Jinfen</creatorcontrib><creatorcontrib>Ren, Yulong</creatorcontrib><creatorcontrib>Li, Jingwei</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Wen, Ziyi</creatorcontrib><creatorcontrib>Jiang, Xinguo</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guo, Liangran</au><au>Fan, Li</au><au>Pang, Zhiqing</au><au>Ren, Jinfen</au><au>Ren, Yulong</au><au>Li, Jingwei</au><au>Chen, Jie</au><au>Wen, Ziyi</au><au>Jiang, Xinguo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2011-08-25</date><risdate>2011</risdate><volume>154</volume><issue>1</issue><spage>93</spage><epage>102</epage><pages>93-102</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><coden>JCREEC</coden><abstract>Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a novel anticancer agent for glioblastoma multiforme (GBM). Some GBM cell lines, however, are relatively resistant to TRAIL. Doxorubicin (DOX) can sensitize GBM cells to TRAIL-induced apoptosis, indicating that the combination of DOX and TRAIL may be an effective strategy to kill TRAIL-resistant GBM cells. However, the therapeutic effect is limited by the short serum half-life of TRAIL, chronic cardiac toxicity of DOX, multidrug resistance (MDR) property of GBM cells and poor drug delivery across the blood-brain barrier (BBB). To solve such problems, combination treatment of TRAIL liposomes (TRAIL-LP) and DOX liposomes (DOX-LP) were developed for the first time. The
in vitro cytotoxicity study indicated that DOX-LP sensitized GBM cell line U87MG but not normal bovine caruncular epithelial cells (BCECs) to TRAIL-LP-induced apoptosis, demonstrating the safety of the combination treatment. This sensitization was accompanied by up-regulation of death receptor 5 (DR5) expression and caspase activation. Furthermore, the combination therapy of TRAIL-LP and DOX-LP displayed stronger anti-GBM effect than free drugs or liposomal drugs alone
in vivo. In summary, the combination treatment reported here showed improved therapeutic effect on GBM. Therefore, it has good potential to become a new therapeutic approach for patients with GBM.
[Display omitted]</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>21609741</pmid><doi>10.1016/j.jconrel.2011.05.008</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-3659 |
| ispartof | Journal of controlled release, 2011-08, Vol.154 (1), p.93-102 |
| issn | 0168-3659 1873-4995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_888113968 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Animals Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use apoptosis Apoptosis - drug effects Biological and medical sciences blood serum blood-brain barrier Blotting, Western caspases Cattle Cell Line, Tumor Cell Survival - drug effects Combination treatment cytotoxicity death Doxorubicin Doxorubicin - administration & dosage Drug Resistance, Neoplasm - drug effects Drug Stability epithelial cells Epithelial Cells - drug effects Epithelial Cells - metabolism Female General pharmacology Glioblastoma Glioblastoma - drug therapy Glioblastoma - metabolism Glioblastoma - pathology half life Humans Liposomes Medical sciences Mice Mice, Inbred BALB C Mice, Nude multiple drug resistance necrosis patients Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments therapeutics TNF-Related Apoptosis-Inducing Ligand - administration & dosage TRAIL Xenograft Model Antitumor Assays |
| title | TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T20%3A01%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TRAIL%20and%20doxorubicin%20combination%20enhances%20anti-glioblastoma%20effect%20based%20on%20passive%20tumor%20targeting%20of%20liposomes&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Guo,%20Liangran&rft.date=2011-08-25&rft.volume=154&rft.issue=1&rft.spage=93&rft.epage=102&rft.pages=93-102&rft.issn=0168-3659&rft.eissn=1873-4995&rft.coden=JCREEC&rft_id=info:doi/10.1016/j.jconrel.2011.05.008&rft_dat=%3Cproquest_cross%3E888113968%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=888113968&rft_id=info:pmid/21609741&rft_els_id=S0168365911003014&rfr_iscdi=true |